CDKN2A and melanoma: Although they display a low mutation rate similar to neuroblastomas, medulloblastomas and ependymomas28, 29, 30, 31, PCCs/PGLs have mutations in TP53, CDKN2A and the RAS/MAPK signalling pathway that have also been found in melanomas and glioblastomas32, 33.